Windlas Biotech

{
  "main_header": {
    "sid": 1003519,
    "name": "Windlas Biotech",
    "stock_name": "Windlas Biotech",
    "full_name": "Windlas Biotech Ltd",
    "name_url": "stocks-analysis/windlas-biotech",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "816.00",
    "chg": 8.35,
    "chgp": "1.03%",
    "dir": 1,
    "prev_price": "807.65",
    "mcapval": "1,670.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543329,
    "symbol": "WINDLAS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE0H5O01029",
    "curr_date": "Jun 19, 03:30 PM",
    "curr_time": "23:05 PM",
    "last_traded_at": "Jun 19, 03:30 PM IST",
    "bse_nse_vol": "46.97 k",
    "exc_status": "Active",
    "traded_date": "Jun 19, 2026",
    "traded_date_str": "2026 06 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/windlas-biotech-1003519-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Windlas Biotech Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/windlas-biotech-ltd-is-rated-sell-4058787",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/WindlasBiotechL_mojoScore_4058787.png",
        "date": "2026-06-17 10:11:14",
        "description": "Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 17 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Windlas Biotech Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/windlas-biotech-ltd-is-rated-sell-4037173",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/WindlasBiotechL_mojoScore_4037173.png",
        "date": "2026-06-06 10:10:33",
        "description": "Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Windlas Biotech Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotech-ltd-valuation-shifts-signal-renewed-price-attractiveness-4029546",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/WindlasBiotechL_valuationdot_4029546.png",
        "date": "2026-06-02 08:05:42",
        "description": "Windlas Biotech Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating despite a recent downgrade in its overall Mojo Grade to Sell. This recalibration in price-to-earnings and price-to-book value metrics, when analysed against historical trends and peer benchmarks, suggests a nuanced investment opportunity within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Windlas Biotech Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/windlas-biotech-ltd-is-rated-sell-4013412",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/WindlasBiotechL_mojoScore_4013412.png",
        "date": "2026-05-26 10:10:52",
        "description": "Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Windlas Biotech Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotech-ltd-valuation-shifts-signal-renewed-price-attractiveness-4009902",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/WindlasBiotechL_valuationdot_4009902.png",
        "date": "2026-05-25 08:01:37",
        "description": "Windlas Biotech Ltd has seen a notable shift in its valuation parameters, moving from fair to attractive territory despite ongoing sector headwinds. With a current price of ₹791.95 and a market cap categorised as small-cap, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Windlas Biotech Gains 1.49%: Mixed Technical Signals and Margin Pressure Shape Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotech-gains-149-mixed-technical-signals-and-margin-pressure-shape-week-4008105",
        "imagepath": "",
        "date": "2026-05-23 12:00:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>18 May:</strong> Stock opens at Rs.777.30, down 0.39% amid broader market weakness</p>\n                    <p><strong>19 May:</strong> Technical momentum shifts amid mixed indicator signals; stock dips to Rs.768.55 (-1.13%)</p>\n                    <p><strong>20 May:</strong> Strong rebound with a 3.84% gain to Rs.798.05, supported by short-term bullish technical cues</p>\n                    <p><strong>21 May:</strong> Profit-taking leads to a 1.84% decline to Rs.783.40 despite Sensex gains</p>\n                    <p><strong>22 May:</strong> Q4 FY26 results reveal margin compression overshadowing revenue growth; stock closes at Rs.791.95 (+1.09%)</p>\n                </div>\n\n       ..."
      },
      {
        "title": "Are Windlas Biotech Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-windlas-biotech-ltd-latest-results-good-or-bad-4007127",
        "imagepath": "",
        "date": "2026-05-22 19:29:07",
        "description": "Windlas Biotech Ltd's latest financial results for Q4 FY26 present a mixed picture of operational performance. The company reported a revenue of ₹238.50 crores, reflecting a year-on-year growth of 17.66% and a quarter-on-quarter increase of 2.32%. This sustained revenue expansion indicates the company's ability to secure contracts within the competitive contract development and manufacturing organization (CDMO) sector. However, the translation of this revenue growth into profitability has been notably weak.\n\nNet profit for the quarter was ₹15.99 crores, which represents a slight decline of 1.78% year-on-year, although there was a quarter-on-quarter improvement of 6.60%. This year-on-year decline in net profit, despite revenue growth, raises concerns about the company's operational efficiency and cost management.\n\nOperating margins have contracted significantly, falling to 10.60%, down from 12.61% a year ear..."
      },
      {
        "title": "Windlas Biotech Q4 FY26: Margin Compression Overshadows Revenue Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/windlas-biotech-q4-fy26-margin-compression-overshadows-revenue-growth-4005257",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/WindlasBiotech_quaterlyResult_4005257.png",
        "date": "2026-05-22 09:55:17",
        "description": "Windlas Biotech Ltd., a contract development and manufacturing organisation (CDMO) in the pharmaceutical sector, reported a mixed performance for the quarter ended March 2026, with net profit declining 1.78% year-on-year to ₹15.99 crores despite revenue growth of 17.66%. The ₹1,603-crore market capitalisation company has witnessed significant margin compression, raising concerns about operational efficiency amidst an otherwise healthy top-line expansion."
      },
      {
        "title": "Windlas Biotech Ltd Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotech-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3998143",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/WindlasBiotechL_technicaldot_3998143.png",
        "date": "2026-05-19 08:07:05",
        "description": "Windlas Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade from Hold to Sell by MarketsMOJO on 4 February 2026, the stock’s technical parameters reveal a cautiously evolving landscape that investors should carefully analyse."
      }
    ],
    "total": 295,
    "sid": "1003519",
    "stock_news_url": "https://www.marketsmojo.com/news/windlas-biotech-1003519"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Windlas Biotech Ltd has declared <strong>116%</strong> dividend, ex-date: 21 Jul 25",
          "dt": "2025-07-21",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Windlas Biotech Ltd is Rated Sell

2026-06-17 10:11:14

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 17 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Windlas Biotech Ltd is Rated Sell

2026-06-06 10:10:33

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Windlas Biotech Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-06-02 08:05:42

Windlas Biotech Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating despite a recent downgrade in its overall Mojo Grade to Sell. This recalibration in price-to-earnings and price-to-book value metrics, when analysed against historical trends and peer benchmarks, suggests a nuanced investment opportunity within the Pharmaceuticals & Biotechnology sector.

Read full news article

Windlas Biotech Ltd is Rated Sell

2026-05-26 10:10:52

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Windlas Biotech Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-05-25 08:01:37

Windlas Biotech Ltd has seen a notable shift in its valuation parameters, moving from fair to attractive territory despite ongoing sector headwinds. With a current price of ₹791.95 and a market cap categorised as small-cap, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value in the Pharmaceuticals & Biotechnology sector.

Read full news article

Windlas Biotech Gains 1.49%: Mixed Technical Signals and Margin Pressure Shape Week

2026-05-23 12:00:04

Key Events This Week

18 May: Stock opens at Rs.777.30, down 0.39% amid broader market weakness

19 May: Technical momentum shifts amid mixed indicator signals; stock dips to Rs.768.55 (-1.13%)

20 May: Strong rebound with a 3.84% gain to Rs.798.05, supported by short-term bullish technical cues

21 May: Profit-taking leads to a 1.84% decline to Rs.783.40 despite Sensex gains

22 May: Q4 FY26 results reveal margin compression overshadowing revenue growth; stock closes at Rs.791.95 (+1.09%)

...

Read full news article

Are Windlas Biotech Ltd latest results good or bad?

2026-05-22 19:29:07

Windlas Biotech Ltd's latest financial results for Q4 FY26 present a mixed picture of operational performance. The company reported a revenue of ₹238.50 crores, reflecting a year-on-year growth of 17.66% and a quarter-on-quarter increase of 2.32%. This sustained revenue expansion indicates the company's ability to secure contracts within the competitive contract development and manufacturing organization (CDMO) sector. However, the translation of this revenue growth into profitability has been notably weak. Net profit for the quarter was ₹15.99 crores, which represents a slight decline of 1.78% year-on-year, although there was a quarter-on-quarter improvement of 6.60%. This year-on-year decline in net profit, despite revenue growth, raises concerns about the company's operational efficiency and cost management. Operating margins have contracted significantly, falling to 10.60%, down from 12.61% a year ear...

Read full news article

Windlas Biotech Q4 FY26: Margin Compression Overshadows Revenue Growth

2026-05-22 09:55:17

Windlas Biotech Ltd., a contract development and manufacturing organisation (CDMO) in the pharmaceutical sector, reported a mixed performance for the quarter ended March 2026, with net profit declining 1.78% year-on-year to ₹15.99 crores despite revenue growth of 17.66%. The ₹1,603-crore market capitalisation company has witnessed significant margin compression, raising concerns about operational efficiency amidst an otherwise healthy top-line expansion.

Read full news article

Windlas Biotech Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

2026-05-19 08:07:05

Windlas Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade from Hold to Sell by MarketsMOJO on 4 February 2026, the stock’s technical parameters reveal a cautiously evolving landscape that investors should carefully analyse.

Read full news article

View All News